Literature DB >> 28724774

Histopathology of Veins Obtained at Hemodialysis Arteriovenous Fistula Creation Surgery.

Charles E Alpers1, Peter B Imrey2,3, Kelly L Hudkins4, Tomasz A Wietecha4, Milena Radeva2, Michael Allon5, Alfred K Cheung6,7,8, Laura M Dember9,10, Prabir Roy-Chaudhury10,11, Yan-Ting Shiu6,12, Christi M Terry6,12, Alik Farber13, Gerald J Beck2,3, Harold I Feldman10,14, John W Kusek15, Jonathan Himmelfarb16.   

Abstract

Stenosis from venous neointimal hyperplasia is common in native arteriovenous fistulas (AVFs). However, the preexisting histologic characteristics of veins at fistula creation, and associations thereof with baseline patient factors, have not been well characterized. In this study, we conducted histologic analysis of a segment of the vein used for anastomosis creation, obtained during AVF creation from 554 of the 602 participants in the multicenter Hemodialysis Fistula Maturation Cohort Study. We quantified intimal and medial areas and lengths of the internal and external elastic lamina by morphometry and assessed venous wall cells by immunohistochemistry, extracellular matrix with Movat stain, and calcium deposition by alizarin red stain. We also studied a representative subset of veins for markers of monocyte/macrophage content, cell proliferation, apoptosis, and neoangiogenesis. Neointima occupied >20% of the lumen in 57% of fully circumferential vein samples, and neointimal hyperplasia associated positively with age and inversely with black race. The neointima was usually irregularly thickened, sometimes concentric, and contained α-smooth muscle actin-expressing cells of smooth muscle or myofibroblast origin. Proteoglycans admixed with lesser amounts of collagen constituted the predominant matrix in the neointima. In 82% of vein samples, the media of vessel walls contained large aggregates of collagen. A minority of veins expressed markers of inflammation, cell proliferation, cell death, calcification, or neoangiogenesis. In conclusion, we observed preexisting abnormalities, including neointimal hyperplasia and prominent accumulation of extracellular matrix, in veins used for AVF creation from a substantial proportion of this cohort.
Copyright © 2017 by the American Society of Nephrology.

Entities:  

Keywords:  arteriovenous access; arteriovenous fistula; dialysis access; pathology

Mesh:

Year:  2017        PMID: 28724774      PMCID: PMC5619951          DOI: 10.1681/ASN.2016050598

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  21 in total

1.  Improved Movat pentachrome stain.

Authors:  W Garvey; A Fathi; F Bigelow; B Carpenter; C Jimenez
Journal:  Stain Technol       Date:  1986-01

Review 2.  The intima. Soil for atherosclerosis and restenosis.

Authors:  S M Schwartz; D deBlois; E R O'Brien
Journal:  Circ Res       Date:  1995-09       Impact factor: 17.367

Review 3.  Why don't fistulas mature?

Authors:  B S Dixon
Journal:  Kidney Int       Date:  2006-08-02       Impact factor: 10.612

4.  Medial fibrosis, vascular calcification, intimal hyperplasia, and arteriovenous fistula maturation.

Authors:  Michael Allon; Silvio Litovsky; Carlton J Young; Mark H Deierhoi; Jeremy Goodman; Michael Hanaway; Mark E Lockhart; Michelle L Robbin
Journal:  Am J Kidney Dis       Date:  2011-06-30       Impact factor: 8.860

5.  Correlation of pre-existing vascular pathology with arteriovenous graft outcomes in hemodialysis patients.

Authors:  Michael Allon; Silvio Litovsky; Carlton J Young; Mark H Deierhoi; Jeremy Goodman; Michael Hanaway; Mark E Lockhart; Michelle L Robbin
Journal:  Am J Kidney Dis       Date:  2013-06-05       Impact factor: 8.860

6.  Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation.

Authors:  S J Shankland; F Eitner; K L Hudkins; T Goodpaster; V D'Agati; C E Alpers
Journal:  Kidney Int       Date:  2000-08       Impact factor: 10.612

Review 7.  Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis.

Authors:  Ahmed A Al-Jaishi; Matthew J Oliver; Sonia M Thomas; Charmaine E Lok; Joyce C Zhang; Amit X Garg; Sarah D Kosa; Robert R Quinn; Louise M Moist
Journal:  Am J Kidney Dis       Date:  2013-10-30       Impact factor: 8.860

Review 8.  Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development.

Authors:  Hiroyuki Hao; Giulio Gabbiani; Marie-Luce Bochaton-Piallat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-08-07       Impact factor: 8.311

Review 9.  Recent insights into the cellular biology of atherosclerosis.

Authors:  Ira Tabas; Guillermo García-Cardeña; Gary K Owens
Journal:  J Cell Biol       Date:  2015-04-13       Impact factor: 10.539

10.  Investigating clinical predictors of arteriovenous fistula functional patency in a European cohort.

Authors:  Agnes Masengu; Alexander P Maxwell; Jennifer B Hanko
Journal:  Clin Kidney J       Date:  2015-12-13
View more
  16 in total

1.  Intimal Hyperplasia, Stenosis, and Arteriovenous Fistula Maturation Failure in the Hemodialysis Fistula Maturation Study.

Authors:  Alfred K Cheung; Peter B Imrey; Charles E Alpers; Michelle L Robbin; Milena Radeva; Brett Larive; Yan-Ting Shiu; Michael Allon; Laura M Dember; Tom Greene; Jonathan Himmelfarb; Prabir Roy-Chaudhury; Christi M Terry; Miguel A Vazquez; John W Kusek; Harold I Feldman
Journal:  J Am Soc Nephrol       Date:  2017-07-14       Impact factor: 10.121

2.  Long-Term Outcomes of Arteriovenous Fistulas with Unassisted versus Assisted Maturation: A Retrospective National Hemodialysis Cohort Study.

Authors:  Timmy Lee; Joyce Zhang Qian; Yi Zhang; Mae Thamer; Michael Allon
Journal:  J Am Soc Nephrol       Date:  2019-10-14       Impact factor: 10.121

3.  Improved Patency of ePTFE Grafts as a Hemodialysis Access Site by Seeding Autologous Endothelial Cells Expressing Fibulin-5 and VEGF.

Authors:  Itai Tzchori; Mizied Falah; Denis Shteynberg; Dana Levin Ashkenazi; Zeev Loberman; Luba Perry; Moshe Y Flugelman
Journal:  Mol Ther       Date:  2018-04-05       Impact factor: 11.454

4.  Moving Beyond the Assumed: Improving Fistula Success Rates.

Authors:  Jay B Wish; Sharon M Moe
Journal:  J Am Soc Nephrol       Date:  2017-07-21       Impact factor: 10.121

5.  Effects of Caveolin-1-ERK1/2 pathway on endothelial cells and smooth muscle cells under shear stress.

Authors:  Lan Jia; Lihua Wang; Fang Wei; Chen Li; Zhe Wang; Haibo Yu; Haiyan Chen; Bo Wang; Aili Jiang
Journal:  Exp Biol Med (Maywood)       Date:  2019-12-06

6.  Mineral Metabolism Disturbances and Arteriovenous Fistula Maturation.

Authors:  Rachel W Kubiak; Leila R Zelnick; Andy N Hoofnagle; Charles E Alpers; Christi M Terry; Yan-Ting Shiu; Alfred K Cheung; Ian H de Boer; Cassianne Robinson-Cohen; Michael Allon; Laura M Dember; Harold I Feldman; Jonathan Himmelfarb; Thomas S Huber; Prabir Roy-Chaudhury; Miguel A Vazquez; John W Kusek; Gerald J Beck; Peter B Imrey; Bryan Kestenbaum
Journal:  Eur J Vasc Endovasc Surg       Date:  2019-04-15       Impact factor: 7.069

Review 7.  Intimal Hyperplasia and Arteriovenous Fistula Failure: Looking Beyond Size Differences.

Authors:  Roberto I Vazquez-Padron; Juan C Duque; Marwan Tabbara; Loay H Salman; Laisel Martinez
Journal:  Kidney360       Date:  2021-08

8.  The anatomical sources of neointimal cells in the arteriovenous fistula.

Authors:  Roberto I Vazquez-Padron; Laisel Martinez; Juan C Duque; Loay H Salman; Marwan Tabbara
Journal:  J Vasc Access       Date:  2021-05-07       Impact factor: 2.283

9.  Abnormalities of vascular histology and collagen fiber configuration in patients with advanced chronic kidney disease.

Authors:  Michael Allon; Silvio H Litovsky; Jason Chieh Sheng Tey; Chad A Sundberg; Yingying Zhang; Zhen Chen; Yun Fang; Alfred K Cheung; Yan-Ting Shiu
Journal:  J Vasc Access       Date:  2018-05-09       Impact factor: 2.283

10.  Vasoreactivity of the Murine External Jugular Vein and Carotid Artery.

Authors:  Jae Min Cho; Yan-Ting Shiu; J David Symons; Timmy Lee
Journal:  J Vasc Res       Date:  2020-06-15       Impact factor: 2.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.